Leland Gershell
Stock Analyst at Oppenheimer
(4.20)
# 316
Out of 4,814 analysts
127
Total ratings
37.39%
Success rate
21.85%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiates: Outperform | $10 | $1.03 | +870.87% | 1 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $12 → $20 | $6.04 | +231.13% | 3 | Mar 11, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $704 | $595.28 | +18.26% | 6 | Feb 28, 2025 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $98 | $58.68 | +67.01% | 3 | Feb 24, 2025 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $76 | $60.52 | +25.58% | 1 | Dec 20, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $190 → $180 | $161.15 | +11.70% | 10 | Nov 15, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $48 → $52 | $20.45 | +154.28% | 2 | Nov 11, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $135 → $147 | $105.13 | +39.83% | 2 | Nov 8, 2024 | |
| VERU Veru Inc. | Reiterates: Outperform | $5 | $0.52 | +854.02% | 8 | Nov 5, 2024 | |
| EPIX ESSA Pharma | Downgrades: Perform | n/a | $1.77 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $73 | $69.21 | +5.48% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $9.63 | +315.37% | 9 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $14.48 | +266.02% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $33.52 | - | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $43 | $11.93 | +260.44% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $3.92 | +665.31% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.36 | +785.61% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $0.81 | +3,003.66% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $13.15 | +113.01% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $3.89 | +542.67% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $30.17 | +141.96% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $1.55 | +1,192.82% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $22.04 | +31.58% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $4.41 | +693.65% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.77 | +1,196.51% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $4.01 | +24.69% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.08 | +1,751.85% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $232.96 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.01 | +1,187.13% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $0.19 | +2,043.62% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.02 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $360,000 | $1.04 | +34,615,284.62% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $13.31 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.92 | +2,504.17% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $9.55 | - | 5 | Mar 31, 2020 |
Quince Therapeutics
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.03
Upside: +870.87%
Trevi Therapeutics
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $6.04
Upside: +231.13%
argenx SE
Feb 28, 2025
Maintains: Outperform
Price Target: $675 → $704
Current: $595.28
Upside: +18.26%
BioMarin Pharmaceutical
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $58.68
Upside: +67.01%
Rhythm Pharmaceuticals
Dec 20, 2024
Initiates: Outperform
Price Target: $76
Current: $60.52
Upside: +25.58%
Ascendis Pharma
Nov 15, 2024
Maintains: Outperform
Price Target: $190 → $180
Current: $161.15
Upside: +11.70%
Dianthus Therapeutics
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $20.45
Upside: +154.28%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $105.13
Upside: +39.83%
Veru Inc.
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.52
Upside: +854.02%
ESSA Pharma
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.77
Upside: -
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $69.21
Upside: +5.48%
Oct 16, 2024
Reiterates: Outperform
Price Target: $40
Current: $9.63
Upside: +315.37%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $14.48
Upside: +266.02%
Oct 3, 2024
Initiates: Perform
Price Target: n/a
Current: $33.52
Upside: -
Sep 25, 2024
Maintains: Outperform
Price Target: $15 → $43
Current: $11.93
Upside: +260.44%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $3.92
Upside: +665.31%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.36
Upside: +785.61%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $0.81
Upside: +3,003.66%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $13.15
Upside: +113.01%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $3.89
Upside: +542.67%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $30.17
Upside: +141.96%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $1.55
Upside: +1,192.82%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $22.04
Upside: +31.58%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $4.41
Upside: +693.65%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.77
Upside: +1,196.51%
Mar 28, 2024
Initiates: Outperform
Price Target: $5
Current: $4.01
Upside: +24.69%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.08
Upside: +1,751.85%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $232.96
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.01
Upside: +1,187.13%
Mar 24, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $0.19
Upside: +2,043.62%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.02
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $360,000
Current: $1.04
Upside: +34,615,284.62%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $13.31
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.92
Upside: +2,504.17%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $9.55
Upside: -